Media coverage about Bruker (NASDAQ:BRKR) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bruker earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 46.7277592936493 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several research analysts recently weighed in on the stock. Citigroup upped their target price on shares of Bruker from $29.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Cowen reaffirmed a “hold” rating and issued a $29.00 target price on shares of Bruker in a report on Friday, November 3rd. Zacks Investment Research raised shares of Bruker from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Wednesday, November 8th. Bank of America raised shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price for the company in a report on Friday, November 3rd. Finally, J P Morgan Chase & Co raised shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price for the company in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $29.64.

Bruker (NASDAQ BRKR) traded up $0.63 on Friday, hitting $34.82. Bruker has a 12-month low of $21.03 and a 12-month high of $36.53. The firm has a market capitalization of $5,416.70, a P/E ratio of 29.76, a price-to-earnings-growth ratio of 2.94 and a beta of 1.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The business had revenue of $435.60 million during the quarter, compared to the consensus estimate of $415.45 million. During the same quarter in the prior year, the firm earned $0.32 EPS. The business’s revenue was up 10.6% on a year-over-year basis. equities research analysts anticipate that Bruker will post 1.19 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 22nd. Shareholders of record on Monday, December 4th will be issued a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a dividend yield of 0.46%. The ex-dividend date of this dividend is Friday, December 1st. Bruker’s dividend payout ratio (DPR) is presently 17.02%.

In other Bruker news, VP Mark Munch sold 21,061 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the transaction, the vice president now owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 35.20% of the stock is owned by corporate insiders.

WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Insider Buying and Selling by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with's FREE daily email newsletter.